Últimas noticias sobre Nasdaq (NASDAQ:NDAQ) Bolsa

Nasdaq

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

Equities

News

Options

Politics

Markets

NDAQ

La Bolsa de Nueva York y Nasdaq cierran el 9 de enero en el Día Nacional de Luto por el expresidente Jimmy Carter. Conoce su legado.

NYSE y Nasdaq cierran en honor al expresidente Jimmy Carter el 9 de enero

Nasdaq Inc

RBC Capital analyst Ashish Sabadra reiterates Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and maintains $95 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Nasdaq, Maintains $95 Price Target

The stock market is closed on Thursday, Jan. 9, 2025 for a National Day of Mourning to honor former President Jimmy Carter whose state funeral will be held at Washington National Cathedral <a href="https://www.benzinga.com/24/12/42725647/markets-will-close-for-president-jimmy-carters-state-funeral-what-you-need-to-know">at 10 a.m. ET.&nbsp;</a>
The Details: The New York Stock Exchange, owned by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), and the Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) have suspended trading in equities and options on Thursday and will resume regular trading hours on Friday.&nbsp;
Lynn Martin, president of NYSE Group, praised Carter's humble roots and life of public service <a href="https://www.benzinga.com/markets/24/12/42717748/will-markets-be-closed-for-former-president-jimmy-carters-funeral-heres-what-investors-should-know">in a statement</a> announcing the closure of the markets.
&#8220;During his noteworthy post-presidential life, President Carter left an enduring legacy of humanitarianism. The NYSE will respectfully honor President Carter&#8217;s lifetime of service to our nation by closing our markets on the National Day of Mourning,&#8221; Martin said.&nbsp;
Read More: <a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a>
Tal Cohen, president of Nasdaq, also released <a href="https://www.benzinga.com/pressreleases/24/12/g42723458/nasdaq-announces-the-closure-of-its-u-s-markets-in-honor-of-a-national-day-of-mourning-for-former-">a statement </a>announcing the closure of all Nasdaq markets.&nbsp;
&#8220;President Carter was an exemplary leader, one who tirelessly continued his efforts to improve the human condition even after his tenure in public office was complete. His contributions will be felt by those around the world for years to come. On behalf of Nasdaq, we extend our deepest condolences to the Carter Family,&#8221; Cohen said.&nbsp;
Cohen <a href="https://www.npr.org/2025/01/09/nx-s1-5251459/u-s-stock-markets-close-mourning-former-president-jimmy-carter">told</a> NPR the financial industry came together to honor Carter's legacy of service.&nbsp;
&#8220;It was a large undertaking,&#8221; Cohen said. &#8220;But we thought it was worth the effort.&#8221;
Thursday's market closures continue a Wall Street tradition dating back to 1865 of closing markets in order to honor deceased presidents. The most recent closure was in 2018 following the death of former President George H.W. Bush.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally </a></li>
</ul>
Photo: Shutterstock

Is The Stock Market Closed For Jimmy Carter's State Funeral?

Raymond James analyst Patrick O'Shaughnessy maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $83 to $84.

Raymond James Maintains Outperform on Nasdaq, Raises Price Target to $84

In the preceding three months, 14 analysts have released ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.71, a high estimate of $98.00, and a low estimate of $80.00. Witnessing a positive shift, the current average has risen by 4.7% from the previous average price target of $83.77.
<img src="https://www.benzinga.com/files/images/story/2025/1736359224_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nasdaq. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nasdaq's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Nasdaq's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Delving into Nasdaq's Background</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Nasdaq's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Nasdaq displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 31.08%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Nasdaq's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.79%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Nasdaq's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.93, Nasdaq faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Nasdaq: Insights From 14 Analyst Reviews

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Clarke Jeffries upgraded the rating for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from Neutral to Overweight and raised the price target from $311 to $357. Autodesk shares closed at $290.82 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Brian Bedell upgraded Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) from Hold to Buy and raised the price target from $80 to $98. Nasdaq shares closed at $76.36 on Tuesday. <a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst John Lovallo upgraded the rating for PulteGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) from Neutral to Buy but lowered the price target from $154 to $148. PulteGroup shares closed at $107.83 on Monday. <a href="https://www.benzinga.com/quote/PHM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Sison upgraded RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) from Equal-Weight to Overweight and raised the price target from $134 to $140. RPM shares closed at $121.74 on Tuesday. <a href="https://www.benzinga.com/quote/RPM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Siti Panigrahi upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Neutral to Outperform and raised the price target from $85 to $140. Twilio shares closed at $109.82 on Tuesday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NDAQ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-1024x578.png" alt="" class="wp-image-723783" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Upgrades

Pre-Market Outlook

Trading Ideas

ADSK

TWLO

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Deutsche Bank analyst Brian Bedell upgrades Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) from Hold to Buy and raises the price target from $80 to $98.

Deutsche Bank Upgrades Nasdaq to Buy, Raises Price Target to $98

Major U.S. stock markets are set to close Jan. 9 to honor the life and legacy of former President Jimmy Carter, who died at the <a href="https://www.benzinga.com/movers-shakers/24/12/42716329/jimmy-carter-the-39th-us-president-who-championed-human-rights-and-peace-in-the-middle-east-had-died">age of 100 Sunday.</a>
What Happened: The New York Stock Exchange, which is owned by the Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), confirmed Monday it <a href="https://www.benzinga.com/markets/24/12/42717748/will-markets-be-closed-for-former-president-jimmy-carters-funeral-heres-what-investors-should-know">will close markets </a>on Jan. 9 as part of President Joe Biden's declaration of a National Day of Mourning for Carter.
Carter served as the 39th president of the United States from 1977 to 1981 and was the oldest living president until his death Sunday.
"Jimmy Carter, with humble roots as a farmer and family man, devoted his life to public service and defending our freedom," NYSE Group President Lynn Martin said.
Martin said the NYSE will honor Carter's "lifetime of service" to the nation with the market closing on the National Day of Mourning and to coincide with his state funeral on Jan. 9 in Washington, D.C.
The U.S. flag above the NYSE will fly at half-staff throughout the mourning period.
The Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) will also close operations on Jan. 9 to honor Carter's life and legacy.
"We mourn the loss of President Carter and will be closing our U.S. markets during the National Day of Mourning to celebrate his life and honor his legacy," Nasdaq President Tal Cohen said.
Read Also<a href="https://www.benzinga.com/general/politics/24/10/41130171/jimmy-carter-at-100-5-things-you-didnt-know-about-the-rock-roll-president">: Jimmy Carter At 100: 5 Things You Didn&#8217;t Know About The Rock &amp; Roll President</a>
Why It's Important: The announcements from the NYSE and Nasdaq follow an American tradition of closing the stock markets after presidents die.
Major stock markets previously closed on Dec. 5, 2018 to coincide with the National Day of Mourning for former President George H.W. Bush. The markets were also closed on Jan. 2, 2007 to honor the life of former President Gerald R. Ford.
The major stock markets close to honor the lives of former presidents and have also closed due to natural disasters and national emergencies in the past.
Markets closed on April 9, 1968 for the National Day of Mourning for Martin Luther King Jr., the only non-president to receive the stock market honor. Markets are now closed every MLK Day, which is celebrated on the third Monday of January.
With the Jan. 9 closure, the stock markets will be closed three days in January: New Year's Day (Jan. 1), the National Day of Mourning (Jan. 9) and MLK Day (Jan. 20).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42716729/jimmy-carter-to-receive-state-funeral-trump-calls-him-truly-a-good-man-biden-mourns-loss-of-extraordinary-leader">Jimmy Carter To Receive State Funeral: Trump Calls Him &#8216;Truly A Good Man,&#8217; Biden Mourns Loss Of &#8216;Extraordinary Leader&#8217;</a></li>
</ul>
Photo via Shutterstock.

Markets Will Close For President Jimmy Carter's State Funeral: What You Need To Know

Analysts' ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) over the last quarter vary from bullish to bearish, as provided by 21 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">14</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $85.86, along with a high estimate of $97.00 and a low estimate of $79.00. Witnessing a positive shift, the current average has risen by 3.93% from the previous average price target of $82.61.
<img src="https://www.benzinga.com/files/images/story/2024/1734717618_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Richard Repetto</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$83.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Nasdaq's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Get to Know Nasdaq Better</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Financial Insights: Nasdaq</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Nasdaq's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.08%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Nasdaq's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.79%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nasdaq's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nasdaq's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Nasdaq's Future

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $86 to $91.

Keefe, Bruyette & Woods Maintains Outperform on Nasdaq, Raises Price Target to $91

On Friday, Nasdaq Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">opens on December 23</a>.
Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, the stock has increased around 8%, underperforming iShares Core S&amp;P Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJH#NYSE">IJH</a>).
The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png" alt="" class="wp-image-694387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;To expand its reach in single-cell analysis and&nbsp;multiomics research, Illumina <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39714633/illumina-buys-fluent-biosciences-to-gain-stronger-foothold-in-single-cell-analysis" rel="noreferrer noopener">acquired privately-held</a> Fluent BioSciences.
Also in March, activist investor&nbsp;Carl Icahn opted against pursuing a fresh challenge to Illumina&#8217;s board, which spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.&nbsp;
Previously, Icahn had expressed intentions to remove additional directors from Illumina&#8217;s board, attributing the company&#8217;s substantial market value decline and the ill-fated $7.1 billion Grail acquisition to mismanagement by the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37671511/gene-sequencing-firm-illumina-escapes-carl-icahns-second-proxy-battle-amid-grail-divestment-effort" rel="noreferrer noopener">existing board members</a>.&nbsp;
Most recently, Illumina reported third-quarter&nbsp;adjusted EPS of $1.14, beating the consensus of $0.88, with sales&nbsp;of $1.08 billion, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41727185/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024" rel="noreferrer noopener">consensus of $1.08 billion</a>.
&#8220;During the third quarter, the Illumina team delivered strong operating results, and revenue met our expectations,&#8221; said&nbsp;Jacob Thaysen, Chief Executive Officer.
&#8220;The near-term macroeconomic environment remains constrained, and we are slightly lowering our 2024 revenue guidance,&#8221; Thaysen added.
Price Action: ILMN stock is down 0.12% at $143.70 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514376/whats-going-on-moderna-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Moderna Stock On Monday?</a></li>
</ul>
Photo via Shutterstock

Health Care

General

GRAL

ILMN

What's Going On With Illumina Stock On Monday?

On Friday, Nasdaq Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">on December 23</a>.
As a result, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the&nbsp;Department of&nbsp;Health and Human Services, is known to be against vaccines and has a track record of making false <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">claims about vaccines</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png" alt="" class="wp-image-694341" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The company has witnessed a decline in its only approved product, Spikevax, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40104375/moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-mark" rel="noreferrer noopener">the COVID-19 vaccine</a>.
However, Moderna witnessed some relief on higher third-quarter sales attributed to higher sales in the U.S. market following the earlier launch of the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">updated COVID-19 vaccine</a>.
Moderna&nbsp;unveiled key updates at its annual R&amp;D Day in September, spotlighting its mRNA-based pipeline and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">revised financial plans</a>.
Faced with commercial challenges, Moderna is adopting a more selective approach to R&amp;D investments. The company anticipates maintaining substantial R&amp;D investment, especially in oncology and rare diseases, while pacing other expenditures.
Moderna is also facing several litigations, including the recently announced patent infringement lawsuit filed by Northwestern University. The lawsuit alleges that the pharmaceutical company used the university's lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
GSK Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41342286/gsk-sues-moderna-alleging-mrna-vaccine-patent-infringement" rel="noreferrer noopener">patents it developed</a>.
Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a></li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Biotech

MRNA

What's Going On With Moderna Stock On Monday?

Barclays analyst Benjamin Budish maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Overweight and raises the price target from $87 to $97.

Barclays Maintains Overweight on Nasdaq, Raises Price Target to $97

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/05/final-trades-nasdaq-the-ibit-and-the-iau.html">Halftime Report Final Trades</a>,&#8221; Bill Baruch of Blue Line Capital picked iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>), saying this &#8220;<a href="https://www.benzinga.com/quote/IBIT">breakout is for real.&#8221;</a>
At the time of writing, Bitcoin price fell around 0.5% to trade at $98,660.13 on Friday.
Liz Young Thomas of SoFi named iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) as her final trade.
Gold futures climbed 0.6% to trade at $2,663.40 an ounce this morning.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management said he likes Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>).
On Oct. 24, Nasdaq reported third-quarter revenue growth of 22% year-on-year to $1.15 billion, missing the analyst consensus estimate of $1.17 billion. The financial services company reported an adjusted EPS of 74 cents, which beat the analyst consensus estimate of 69 cents. The stock price slid after the print. Nasdaq&#8217;s Annualized Recurring Revenue (ARR) increased 31% year-over-year to $2.74 billion.
Nasdaq CEO Adena Friedman praised the "fourth consecutive quarter of double-digit Solutions growth <a href="https://www.benzinga.com/news/earnings/24/10/41517629/nasdaq-sees-recurring-revenue-soar-31-in-q3-solutions-rake-in-872m">with strong overall quarterly performance."</a>
Price Action:
<ul>
<li>iShares Bitcoin Trust slipped by 0.04% on Thursday.</li>
<li>Nasdaq shares rose by 0.5% to settle at $81.27 during Thursday's session.</li>
<li>iShares Gold Trust fell by 0.7% on Thursday.</li>
</ul>
Check This Out<a href="https://www.benzinga.com/24/12/42357598/dow-dips-more-than-200-points-ahead-of-jobs-report-investor-sentiment-declines-fear-greed-index-remains-in-greed-zone">: </a>
<ul>
<li><a href="https://www.benzinga.com/24/12/42357598/dow-dips-more-than-200-points-ahead-of-jobs-report-investor-sentiment-declines-fear-greed-index-remains-in-greed-zone">Dow Takes A Breather After Record Close, Dips Over 200 Points Ahead Of Jobs Report: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Topics

IBIT

Bitcoin 'Breakout Is For Real,' Analyst Says On CNBC's Final Trades

CNBC Halftime Report Final Trades: Nasdaq, iShares Bitcoin Trust, iShares Gold Trust Shares of the iShares Gold Trust

21 analysts have shared their evaluations of Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.0, with a high estimate of $93.00 and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 5.88% increase from the previous average price target of $80.28.
<img src="https://www.benzinga.com/files/images/story/2024/1732557667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Nasdaq among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Richard Repetto</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nasdaq's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Unveiling the Story Behind Nasdaq</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Nasdaq's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Nasdaq showcased positive performance, achieving a revenue growth rate of 31.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Nasdaq's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Nasdaq's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Nasdaq's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Nasdaq

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On Nasdaq with Outperform Rating

On Tuesday&#8217;s CNBC &#8220;<a href="https://www.cnbc.com/video/2024/11/19/final-trades-nasdaq-d-r-horton-crowdstrike-and-the-ijr.html">Halftime Report Final Trades</a>,&#8221; Josh Brown of Ritholtz Wealth Management named Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) as his final trade.
On Oct. 25, Nasdaq reported third-quarter revenue growth of 22% year-on-year to $1.15 billion, missing the analyst consensus estimate of $1.17 billion. The financial services company reported an adjusted EPS of 74 cents, which beat the analyst consensus estimate of 69 cents.
Jason Snipe of Odyssey Capital Advisors said D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is down 17% and he likes this entry point.
On Oct. 29, D.R. Horton reported fourth-quarter results. Sales fell 5% year-over-year to $10.0 billion, missing the consensus of $10.2 billion. Net sales orders increased 1% to 19,035 homes and decreased 2% in value at $7.1 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners picked iShares Core S&amp;P Small-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJR#NYSE">IJR</a>).
Stephanie Link of Hightower Advisors said CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is still down 10% from its highs.
CrowdStrike will release financial results for its fiscal third quarter 2025 ended Oct. 31, after the closing bell on Tuesday, Nov. 26. Analysts expect the company to report quarterly earnings of 81 cents per share on revenue of $983.05 million.
Price Action:
<ul>
<li>Nasdaq shares gained 0.5% to close at $80.16 on Tuesday.</li>
<li>D.R. Horton shares gained by 0.5% to settle at $162.30 during Tuesday's session.</li>
<li>iShares Core S&amp;P Small-Cap ETF gained by 0.2% during Tuesday's session.</li>
<li>CrowdStrike shares gained by 3% to settle at $353.29.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Long Ideas

Media

CRWD

CrowdStrike, Nasdaq, D.R. Horton And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Nasdaq, D.R. Horton, CrowdStrike, iShares Core S&P Small-Cap ETF

RBC Capital analyst Ashish Sabadra reiterates Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and maintains $88 price target.

RBC Capital Reiterates Outperform on Nasdaq, Maintains $88 Price Target

Applovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) will join the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted Index next Monday <a href="https://www.benzinga.com/pressreleases/24/11/g41862072/applovin-corporation-to-join-the-nasdaq-100-index-beginning-november-18-2024">prior to the market open</a>. 
The Nasdaq-100 inclusion caps a significant year for the company which has seen its stock price rise <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution">more than 600%. </a>
What To Know: Applovin shares gained more than 75% last week after the company reported blockbuster <a href="https://www.benzinga.com/news/earnings/24/11/41813088/applovin-stock-is-taking-off-thursday-whats-going-on">third-quarter earnings </a>on Wednesday. Applovin beat analysts' estimates on the top and bottom lines and increased its share buyback program by $2 billion.&nbsp;
The company reported 39% total revenue growth year-over-year with Software platform revenue growth of 66% driven by Applovin's Axon 2.0 AI-based advertising engine powering its AppDiscovery platform.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41850890/super-micro-delisting-risk-puts-1-7-billion-bond-repayment-on-the-line">Super Micro Delisting Risk Puts $1.7 Billion Bond Repayment On The Line</a>
On the company's earnings call, Applovin management attributed the company's growth to its AI- powered technology driving increased demand from advertisers who report positive impacts on campaign performance.&nbsp;
"We've got the largest mediation solution in the sector and our teams built maybe the most innovative advertising technology that the world's yet seen," cofounder, chairman, and CEO Adam Foroughi.&nbsp;
Loop Capital analyst Rob Sanderson sees Applovin shares continuing to climb after the stock is added to the Nasdaq-100 Index next Monday. Yesterday Sanderson maintained Applovin as a Buy and raised his price target on the stock from $181 to $385.
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Applovin shares are down 1.28% at $282.75 at the time of publication Tuesday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

Movers

Applovin Stock Up 600% In 2024, Joins Nasdaq-100 Index Monday

Despite Friday's strong upward trend, stocks ended the week with losses. The S&P 500 (SPX) was down by 0.48% and the Dow Jones Industrial Average (...

3 Economic Events That Could Affect Your Portfolio This Week, January 6-10, 2025

Piper Sandler analyst Patrick Moley maintained a Buy rating on Nasdaq (NDAQ – Research Report) today and set a price target of $80.00. The company'...

Piper Sandler Keeps Their Buy Rating on Nasdaq (NDAQ)

CFTC Chairman Rostin Behnam stated: "After more than seven years at the U.S. Commodity Futures Trading Commission, I will be stepping down from my ...

CFTC Chairman Rostin Behnam announces planned departure

Nasdaq (NDAQ – Research Report) received a Buy rating and a price target from Deutsche Bank analyst Brian Bedell today. The company's shares closed...

Positive Report for Nasdaq (NDAQ) from Deutsche Bank

Deutsche Bank analyst Brian Bedell upgraded Nasdaq (NDAQ) to Buy from Hold with a price target of $98, up from $80. The main driver of our upgrade ...

Nasdaq upgraded to Buy from Hold at Deutsche Bank

In a report released today, Daniel Fannon from Jefferies maintained a Hold rating on Nasdaq (NDAQ – Research Report), with a price target of $75.00...

Jefferies Keeps Their Hold Rating on Nasdaq (NDAQ)

Nasdaq U.S. matched equity volume jumps 9.3% M/M in December

In a report released today, Kyle Voigt from KBW maintained a Buy rating on Nasdaq (NDAQ – Research Report), with a price target of $91.00. The comp...

KBW Sticks to Its Buy Rating for Nasdaq (NDAQ)

RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) yesterday and set a price target of $95.00. The compa...

RBC Capital Remains a Buy on Nasdaq (NDAQ)

Raymond James analyst Patrick O'Shaughnessy raised the firm's price target on Nasdaq (NDAQ) to $84 from $83 and keeps an Outperform rating on the s...

Comments

Nasdaq

Noticias

Últimas noticias sobre Nasdaq (NASDAQ:NDAQ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL